Viridian Therapeutics, Inc. (VRDN)
- Previous Close
13.03 - Open
12.86 - Bid 12.68 x 400
- Ask 12.73 x 300
- Day's Range
12.20 - 12.95 - 52 Week Range
10.93 - 28.99 - Volume
958,729 - Avg. Volume
901,208 - Market Cap (intraday)
797.148M - Beta (5Y Monthly) 1.10
- PE Ratio (TTM)
-- - EPS (TTM)
-5.31 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
38.27
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
www.viridiantherapeutics.comRecent News: VRDN
Performance Overview: VRDN
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VRDN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VRDN
Valuation Measures
Market Cap
797.15M
Enterprise Value
547.34M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.81k
Price/Book (mrq)
3.38
Enterprise Value/Revenue
1.74k
Enterprise Value/EBITDA
-2.33
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-34.37%
Return on Equity (ttm)
-56.80%
Revenue (ttm)
314k
Net Income Avi to Common (ttm)
-237.73M
Diluted EPS (ttm)
-5.31
Balance Sheet and Cash Flow
Total Cash (mrq)
477.37M
Total Debt/Equity (mrq)
4.99%
Levered Free Cash Flow (ttm)
-102.82M